Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...
Recent long-term data on pembrolizumab and nivolumab has reaffirmed the benefits of anti-PD-1 therapies in managing residual melanoma. However, Funck-Brentano cautioned, “Most patients do not ...
Medpage Today on MSN11d
Combination Slows Metastatic CRC Progression Better Than Single ImmunotherapyMedian duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers.New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is ...
Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...
This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback